Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
Ginkgo Bioworks Holdings (DNA) Stock Price & Analysis
1,809 Followers
DNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $2.55
Previous Close$0.81
Volume31.43M
Average Volume (3M)35.92M
Market Cap
$1.78B
Enterprise Value$1.06B
Total Cash (Recent Filing)$944.07M
Total Debt (Recent Filing)$221.84M
Price to Earnings (P/E)-1.9
Beta2.76
Next Earnings
Aug 13, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding2,211,277,968
10 Day Avg. Volume58,226,770
30 Day Avg. Volume35,923,061
Standard Deviation0.21
R-Squared0.17
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.83
Price to Sales (P/S)5.47
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$1.33Price Target Upside65.09% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering5
Ginkgo Bioworks Holdings News
PremiumCompany Announcements
Ginkgo Bioworks: Addressing NYSE Standards Noncompliance
Bulls Say, Bears Say
Bulls Say
Financial OutlookGinkgo forecasts a considerable increase in total revenue for 2024, driven by its Cell Engineering services and supported by robust contracts from the biopharma and government sectors.
Product And Service ExpansionGinkgo's new 'Lab Data as a Service' provides biopharma customers with the ability to generate and retain access to their data, ensuring transparency with clear pricing and project timelines.
Strategic PartnershipsGinkgo's expanded alliance with Novo Nordisk aims to enhance the manufacturing of therapeutics for chronic diseases, demonstrating the company's commitment to growing collaborations.
Bears Say
Financial PerformanceGinkgo posted Q4 revenues of $35M, a significant 65% year-on-year decline, and FY23 revenues of $251M, a 47% decrease from the previous year, falling short of market expectations.
Guidance And StrategyAnalysts express concerns as Ginkgo undergoes a strategic shift in its commercial monetization approach, casting doubt on future business predictability.
Operational ChangesGinkgo's announcement of substantial workforce reductions and a significant cut in its physical footprint signals potential internal challenges and cost pressures.
---
Ownership Overview
8.68% Insiders
11.47% Mutual Funds
71.72% Other Institutional Investors
8.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $0.72 and its highest was $2.54 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Currently, no data Available
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Aug 13, 2024 which is in 86 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on May 09, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.003.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -$0.08.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 1,709,064,000 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went down -17.391%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Among the largest hedge funds holding Ginkgo Bioworks Holdings’s share is ARK Investment Management LLC. It holds Ginkgo Bioworks Holdings’s shares valued at 336M.
---
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.33 (65.09% Upside)
$1.33 (65.09% Upside)
Blogger Sentiment
Bullish
DNA Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 16.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $822.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.61%
12-Months-Change
Fundamentals
Return on Equity
-65.81%
Trailing 12-Months
Asset Growth
-34.56%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
---
DNA Company Deck
---
DNA Earnings Call
Q1 2024
0:00 / 0:00
---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$1.33
▲(65.09% Upside)
Technical Analysis
Best Analysts Covering DNA
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-31.11%
downgraded a sell rating 5 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -31.11% per trade.
---